Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Prudential (PRU) closed at $88.78 in the latest trading session, marking a -0.42% move from the prior day.

Prudential announced that annual premium equivalent (APE) sales were up 40% during the first nine months of September, at $4.4 billion. This was driven by strength in Hong Kong, it said, where ...

Shares of Prudential Financial Inc. PRU have lost 11.4% in the past year, underperforming the industry, the Zacks S&P 500 composite and the Finance sector’s growth of 8.1%, 11.4% and 19.5% ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Prudential Financial Inc (Symbol: PRU), where a total of 7,660 contracts have traded so ...

But Pru shares trade on the same nine times forward earnings multiple they did when UK business M&G was split off in 2019. True, Pru’s discount with peer AIA has shrunk.

The encouraging long-term efficacy and safety associated with nemolizumab (IL-31 inhibitor) in prurigo nodularis was supported by a second set of data showing long-term benefit in atopic dermatitis.

Prudential plans to leave its longtime home in Pru Plaza, the two-tower complex at 130 East Randolph Street for John O’Donnell’s 150 North Riverside.

The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” ...

Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the patho ...

The approval stipulates use in adults with prurigo nodularis, a skin condition characterized by chronic itch, nodules covering large areas of the body, and poor sleep quality. Driven by IL-31 ...

The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for prurigo nodularis, Sanofi and Regeneron announced. A chronic inflammatory skin condition affecting about ...